Thrive Earlier Detection is a healthcare company that integrates earlier cancer detection into routine medical care.

Thrive is a healthcare company focused on saving lives by making earlier detection of cancer a routine part of medical care. It develops CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of the disease. CancerSEEK will serve as the core of Thrive‚Äôs integrated cancer information offering. The company was launched in 2019 by Third Rock Ventures, with funding from additional investors Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group, Camden Partners Nexus, Cowin Venture, Exact Sciences, and Gamma3.

Thrive Earlier Detection

Clinical Trial Manager

Associate Clinical Trial Manager

X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.

X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment. The company is developing two unique programs such as drug candidate, X4P-001, has clinical experience in over 70 subjects, and is advancing into Phase 1/2 trials in refractory clear cell renal cell carcinoma (ccRCC) and refractory epithelial ovarian cancer (EOC), the second program, X4P-002, is a unique series of late lead molecules that penetrate the blood-brain barrier. They will pursue early clinical development in glioblastoma multiforme (GBM), a rare form of lethal brain cancer, for the X4P-002 program.

X4 Pharmaceuticals

Senior Clinical Trial Manager

Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.

Tango Therapeutics operator of a biotechnology company created to discover novel drug targets and deliver the next generation of targeted therapies to people with cancer. The company's research leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer that are focused on three core areas, including counteracting tumor suppressor gene loss, reversing the ability of cancer cells to evade the immune system and identifying novel combinations, enabling patients to get therapies that are more effective than single-agent therapy.

Tango Therapeutics

Cognito Therapeutics is a neurotechnology company that is developing disease-modifying treatments for CNS illnesses.

Cognito Therapeutics is a clinical-stage neurotechnology business focused on creating disease-modifying pharmaceutical methods for the treatment of neurodegenerative illnesses. Li-Huei Tsai and Ed Boyden, MIT Professors, and scientific founders, created its non-invasive neuromodulation platform. The Company's primary therapy is now being studied in a pivotal study for Alzheimer's Disease and has been designated as a Breakthrough Device by the FDA.

Cognito Therapeutics

Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.

Beam Therapeutics is a biotechnology company engaged in creating genetic medicines based on its base editing technology. It is pioneering the use of base editing, a potential new class of precision genetic medicines, with a vision of providing life-long cures to patients suffering from serious diseases. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the dna.

Location

Company Stage

Age of Data

Experience

Industry

Company

Clinical Trial Manager

Thrive Earlier Detection

$67k - $109k

$67,000 - $109,000

Associate Clinical Trial Manager

$67k - $109k

$67,000 - $109,000

X4 Pharmaceuticals

N/A

N/A

Senior Clinical Trial Manager

N/A

N/A

Tango Therapeutics

N/A

N/A

Clinical Trial Manager

N/A

N/A

Cognito Therapeutics

N/A

N/A

Clinical Trial Manager

N/A

N/A

Beam Therapeutics

N/A

N/A

Senior Clinical Trial Manager

N/A

N/A